Article Data

  • Views 462
  • Dowloads 124

Systematic Reviews

Open Access

Evaluation of the efficacy of stem cell therapy in erectile dysfunction after radical prostatectomy: a comprehensive systematic review

  • Saad Thamer Alshahrani1
  • Omar Safar1,*,
  • Nazal A Almsaoud2
  • Adel Elatreisy1,3
  • Ahmed Ibrahim4
  • Sulaiman M Alkhaldi2
  • Abdulhamid M Alkhaldi2
  • Raed Alwadai5
  • Muath Almurayyi6
  • Saeed A Asiri1
  • Abdulaziz M Alqahtani1
  • Abdullah Saleh Alshafi1
  • Saleh Alghamdi1
  • Ahmed Al-Hadi1
  • Basel Hakami7,8
  • Meshari A. Alzahrani9

1Urology Department, Armed Forces Hospital Southern Region, 62413 Khamis Mushayt, Saudi Arabia

2Urology Department, Prince Mutaib Bin Abdulaziz Hospital, 72341 Sakakah, Saudi Arabia

3Urology Department, Faculty of Medicine, Al-Azher University, 11754 Cairo, Egypt

4Urology Department, University of Montreal, 6128 Montreal, QC, Canada

5Urology Department, King Abdullah Hospital, 67714 Bishah, Saudi Arabia

6Urology Department, King Khaled University Medical City-Abha, 62523 Abha, Saudi Arabia

7Urology Department, King Faisal Medical City for Southern Region KFM City, 62527 Abha, Saudi Arabia

8Urology Department, King Fahad Central Hospital, 82666 Jazan, Saudi Arabia

9Urology Department, College of Medicine, Majmaah University, 11952 Al-Majmaah, Saudi Arabia

DOI: 10.22514/jomh.2024.035 Vol.20,Issue 3,March 2024 pp.25-31

Submitted: 03 November 2023 Accepted: 12 December 2023

Published: 30 March 2024

*Corresponding Author(s): Omar Safar E-mail:


Around 68% patients undergoing radical prostatectomy face postoperative erectile dysfunction. This systematic review aims to investigate the studies pertaining to efficacy of stem cell therapy in alleviating erectile dysfunction (ED) of radical prostatectomy (RP) patients. Furthermore, it provides evidence-based potential benefits of stem cell therapy in addressing erectile dysfunction of those patients. A systematic literature search from PubMed, Google Scholar, Science Direct and databases was conducted for the clinical trials evaluating efficacy and safety of stem cell therapy in post-prostatectomy erectile dysfunction. The inclusion criteria pertained to the studies reporting pre- and post-outcome erectile function and safety results. Cochrane Robins I was employed for the quality and bias risk. Four studies were finally included. The studies were of high quality as revealed from the quality assessment results. They were the non-randomized human-based clinical trials. Patients follow-up ranged from 3 to 12 months. Intercourse satisfaction scores were improved after 6 and 12 months of stem cell therapy. No serious adversities were reported during and after the study period. It was thus a safe therapeutic option as per these results. This study evaluated the role of stem cell therapy in post-RP ED. The included studies depicted its efficacy and safety. The information on stem cell therapy for ED was limited, however it could provide foundation for future research. Large-scale human studies with robust research designs would bring more objectivity and conclusive evidence.


Post-prostatectomy; Erectile dysfunction; Stem-cell therapy

Cite and Share

Saad Thamer Alshahrani,Omar Safar,Nazal A Almsaoud,Adel Elatreisy,Ahmed Ibrahim,Sulaiman M Alkhaldi,Abdulhamid M Alkhaldi,Raed Alwadai,Muath Almurayyi,Saeed A Asiri,Abdulaziz M Alqahtani,Abdullah Saleh Alshafi,Saleh Alghamdi,Ahmed Al-Hadi,Basel Hakami,Meshari A. Alzahrani. Evaluation of the efficacy of stem cell therapy in erectile dysfunction after radical prostatectomy: a comprehensive systematic review. Journal of Men's Health. 2024. 20(3);25-31.


[1] Capogrosso P, Salonia A, Briganti A, Montorsi F. Postprostatectomy erectile dysfunction: a review. The World Journal of Men’s Health. 2016; 34: 73.

[2] Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, et al. Erectile dysfunction. Nature Reviews Disease Primers. 2016; 2: 16003.

[3] Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: a meta-analysis. The Journal of Sexual Medicine. 2009; 6: 2538–2546.

[4] Bratu O, Oprea I, Marcu D, Spinu D, Niculae A, Geavlete B, et al. Erectile dysfunction post-radical prostatectomy—a challenge for both patient and physician. Journal of Medicine and Life. 2017; 10: 13–18.

[5] Wani MM, Rai BP, Webb WR, Madaan S. Is there a role for stem cell therapy in erectile dysfunction secondary to cavernous nerve injury? Network meta-analysis from animal studies and human trials. Therapeutic Advances in Urology. 2022; 14: 175628722210869.

[6] Mangır N, Türkeri L. Stem cell therapies in post-prostatectomy erectile dysfunction: a critical review. The Canadian Journal of Urology. 2017; 24: 8609–8619.

[7] Asker H, Yilmaz‐Oral D, Oztekin CV, Gur S. An update on the current status and future prospects of erectile dysfunction following radical prostatectomy. The Prostate. 2022; 82: 1135–1161.

[8] Protogerou V, Chrysikos D, Karampelias V, Spanidis Y, Sara EB, Troupis T. Erectile dysfunction treatment using stem cells: a review. Medicines. 2021; 8: 2.

[9] Xu P, Wang YH. Prevention and treatment of erectile dysfunction after prostatectomy: an update. National Journal of Andrology. 2017; 23: 656–662. (In Chinese)

[10] Siregar S, Novesar AR, Mustafa A. Application of stem cell in human erectile dysfunction—a systematic review. Research and Reports in Urology. 2022; 14: 379–388.

[11] Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. The BMJ. 2016; 355: i4919.

[12] Yiou R, Hamidou L, Birebent B, Bitari D, Lecorvoisier P, Contremoulins I, et al. Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. European Urology. 2016; 69: 988–991.

[13] Yiou R, Hamidou L, Birebent B, Bitari D, Le Corvoisier P, Contremoulins I, et al. Intracavernous injections of bone marrow mononucleated cells for postradical prostatectomy erectile dysfunction: final results of the INSTIN clinical trial. European Urology Focus. 2017; 3: 643–645.

[14] Haahr MK, Harken Jensen C, Toyserkani NM, Andersen DC, Damkier P, Sørensen JA, et al. A 12-month follow-up after a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. Urology. 2018; 121: 203.e6–203.e13.

[15] Haahr MK, Jensen CH, Toyserkani NM, Andersen DC, Damkier P, Sørensen JA, et al. Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. EBioMedicine. 2016; 5: 204–210.

[16] Hansen ST, Lund M, Ostergaard LD, Lund L. Role of regenerative therapies on erectile dysfunction after radical prostatectomy. International Journal of Impotence Research. 2021; 33: 488–496.

[17] Yiou R. Stem-cell therapy for erectile dysfunction. Bio-Medical Materials and Engineering. 2017; 28: S81–S85.

[18] Pérez-Aizpurua X, Garranzo-Ibarrola M, Simón-Rodríguez C, García-Cardoso JV, Chávez-Roa C, López-Martín L, et al. Stem cell therapy for erectile dysfunction: a step towards a future treatment. Life. 2023; 13: 502.

[19] Vakalopoulos I, Memmos D, Mykoniatis I, Toutziaris C, Dimitriadis G. Stem cell therapy in erectile dysfunction: science fiction or realistic treatment option? Hormones. 2018; 17: 315–320.

[20] Gur S, Abdel-Mageed AB, Sikka SC, Hellstrom WJG. Advances in stem cell therapy for erectile dysfunction. Expert Opinion on Biological Therapy. 2018; 18: 1137–1150.

[21] Albersen M, Weyne E, Bivalacqua TJ. Stem cell therapy for erectile dysfunction: progress and future directions. Sexual Medicine Reviews. 2013; 1: 50–64.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.7 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (

Submission Turnaround Time